uniQure N.V. (QURE)
NASDAQ: QURE · Real-Time Price · USD
14.31
-0.08 (-0.56%)
Apr 24, 2025, 3:03 PM EDT - Market open
uniQure Revenue
In the year 2024, uniQure had annual revenue of $27.12M with 71.17% growth. uniQure had revenue of $5.22M in the quarter ending December 31, 2024, a decrease of -21.95%.
Revenue (ttm)
$27.12M
Revenue Growth
+71.17%
P/S Ratio
25.81
Revenue / Employee
$129,756
Employees
209
Market Cap
773.84M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 27.12M | 11.28M | 71.17% |
| Dec 31, 2023 | 15.84M | -90.64M | -85.12% |
| Dec 31, 2022 | 106.48M | -417.52M | -79.68% |
| Dec 31, 2021 | 524.00M | 486.49M | 1,296.82% |
| Dec 31, 2020 | 37.51M | 30.23M | 415.23% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.90B |
QURE News
- 3 days ago - uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130 - Seeking Alpha
- 5 days ago - uniQure: AMT-130 For HD Progresses Forward With Q2 2025 FDA Meeting - Seeking Alpha
- 7 days ago - Why Is Gene Therapy Developer uniQure Stock Trading Higher On Thursday? - Benzinga
- 7 days ago - uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease - GlobeNewsWire
- 2 months ago - uniQure Announces 2024 Financial Results and Highlights Recent Company Progress - GlobeNewsWire
- 2 months ago - uniQure N.V.: A Potential Huntington's Play - Seeking Alpha
- 2 months ago - uniQure: Gene Therapy Specialist Looks Set For Upside As Huntington's Approval Beckons - Seeking Alpha
- 2 months ago - uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years - Benzinga